Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Allogeneic transplantation in fit older adults is feasible and encouragingly efficacious. Post-remission data from the prospective ECOG-ACRIN (E2906) clinical study

Y Ofran;Z Sun;J Rowe;D Claxton;M Tallman;D Arber;A Melnick;R Levine;E Paietta;J Godwin;H Lazarus;S Luger;J Foran;M Litzow American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #413

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

J Foran;Z Sun;D Claxton;H Lazarus;D Arber;JM Rowe;E Paietta;J Racevskis;J Altman;S Luger;A Al-Kali;H Zheng;K Pratz;E Broun;B Powell;K O'Dwyer;J Godwin;Y Ofran;M Litzow;M Tallman Blood (2019) 134 (Supplement_1): 115 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL)), oral

Prospective study of HLA-matched donor availability and survival in remission after AML in older adults: 1st planned analysis from ECOG-ACRIN E2906 phase iii randomized trial in patients age =60 years.

J Foran;Z Sun;D Claxton;S Luger;J Altman;K Pratz;J Godwin;E Paietta;J Rowe;M Litzow;H Lazarus;M Tallman HemaSphere 378 2018;s(S1); European Hematology Association 23rd Congress (June 14-17, 208, Stockholm, Sweden), oral

Prospective Study of Minimal Residual Disease (MRD) Status and Outcome After Complete Remission (CR) Following Intensive Remission Induction Therapy in Older Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years

J Foran;E Paietta;X Sun;J Racevskis;D Claxton;H Lazurus;M Thomas;A Melnick;R Levine;D Arber;Y Zhang;J Rowe;JE Godwin;J Altman;A Al-Kali;H Zheng;K Pratz;ER Broun;B Powell;K O'Dwyer;M Tallman;S Luger;M Litzow Blood 132:437; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, oral/plenary

FLT3-ITD Mutations Are Prevalent in Older Adults with Acute Myeloid Leukemia (AML) and Significantly Impact Outcome After Intensive Therapy: Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years

J Foran;X Sun;E Paietta;J Racevskis;D Claxton;H Lazurus;D Arber;Y Zhang;J Rowe;J Godwin;J Altman;A Al-Kali;H Zheng;ER Broun;B Powell;K O'Dwyer;M Tallman;M Litzow;J Pratz;S Luger Blood 132:3995American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster

Phase III randomized trial of clofarabine as induction and post-remission therapy vs. standard daunorubicin & cytarabine induction and intermediate dose cytarabine post-remission therapy, followed by decitabine maintenance vs. observation in newly-diagnosed acute myeloid leukemia in older adults (Age>/=60 Years): A trial of the ECOG-ACRIN Cancer Research Group (E2906)

J Foran;Z Sun;M Tallman;D Claxton;HM Lazarus;ML Thomas;AM Melnick;RL Levine;E Paietta;D Arber;Y Zhang;JM Rowe;JE Godwin;J Altman;S Luger;A Al-Kali;ER Broun;BL Powell;KM O'Dwyer;MR Litzow Blood 126(23):217; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;